Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Lyell Immunopharma Inc's Business Segments
Lyell Immunopharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable segment | $ 0 | 100% |
Description of Lyell Immunopharma Inc
Lyell Immunopharma Inc is a biotechnology company focused on the development of next-generation cell therapies for cancer treatment. The company is headquartered in South San Francisco, California, and is led by CEO and co-founder, Rick Klausner. The company was founded in 2018, and has raised over $493 million in funding to date.
Lyell Immunopharma's mission is to transform cancer treatment by developing new cell therapies that enhance the body's natural immune system to fight cancer. The company is focused on developing personalized cell therapies that target specific types of cancer, improving the effectiveness of current treatments and reducing the side effects associated with traditional treatments.
Lyell Immunopharma is developing a platform that combines the latest advances in synthetic biology with sophisticated gene editing technologies to create powerful immune cells that can specifically target cancer cells. The company's proprietary technology is based on a novel approach called Synthetic Control of Cellular Circuits (SynC3), which enables the design of precise and customizable cell therapies that can respond to changing conditions within the body.
Lyell Immunopharma's lead product candidate is LY-501, a personalized cell therapy that targets solid tumors. The company is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of LY-501 in patients with advanced solid tumors. The company also has several other programs in preclinical development, including CAR-T and TCR therapies for different types of cancer.
Lyell Immunopharma has received significant funding from several high-profile investors, including ARCH Venture Partners, Foresite Capital, and the Alaska Permanent Fund. The company also has partnerships with several leading academic institutions, including the University of California, San Francisco, and the Massachusetts Institute of Technology.
In summary, Lyell Immunopharma is a biotechnology company that is focused on developing next-generation cell therapies for cancer treatment. The company's mission is to transform cancer treatment by developing personalized cell therapies that enhance the body's natural immune system to fight cancer. With its proprietary SynC3 platform, the company is developing powerful and customizable cell therapies that can respond to changing conditions within the body. The company's lead product candidate, LY-501, is currently in clinical trials and the company has several other programs in preclinical development.
Lyell Immunopharma's mission is to transform cancer treatment by developing new cell therapies that enhance the body's natural immune system to fight cancer. The company is focused on developing personalized cell therapies that target specific types of cancer, improving the effectiveness of current treatments and reducing the side effects associated with traditional treatments.
Lyell Immunopharma is developing a platform that combines the latest advances in synthetic biology with sophisticated gene editing technologies to create powerful immune cells that can specifically target cancer cells. The company's proprietary technology is based on a novel approach called Synthetic Control of Cellular Circuits (SynC3), which enables the design of precise and customizable cell therapies that can respond to changing conditions within the body.
Lyell Immunopharma's lead product candidate is LY-501, a personalized cell therapy that targets solid tumors. The company is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of LY-501 in patients with advanced solid tumors. The company also has several other programs in preclinical development, including CAR-T and TCR therapies for different types of cancer.
Lyell Immunopharma has received significant funding from several high-profile investors, including ARCH Venture Partners, Foresite Capital, and the Alaska Permanent Fund. The company also has partnerships with several leading academic institutions, including the University of California, San Francisco, and the Massachusetts Institute of Technology.
In summary, Lyell Immunopharma is a biotechnology company that is focused on developing next-generation cell therapies for cancer treatment. The company's mission is to transform cancer treatment by developing personalized cell therapies that enhance the body's natural immune system to fight cancer. With its proprietary SynC3 platform, the company is developing powerful and customizable cell therapies that can respond to changing conditions within the body. The company's lead product candidate, LY-501, is currently in clinical trials and the company has several other programs in preclinical development.
Lyell Immunopharma Inc. is a pioneering biotechnology company based in California that specializes in the development of innovative cell-based therapies aimed at treating cancer. Their approach centers on harnessing and enhancing the immune system’s natural ability to fight cancer, particularly through personalized and targeted therapeutic strategies. This expansive overview provides a detailed description of the company’s segments, products, and services.
Segments:
1. Cell Therapy:
This primary segment concentrates on crafting personalized cell-based therapies tailored for individual patients. By employing advanced methods such as engineered T cell receptors (TCRs) and chimeric antigen receptor (CAR)-T cell therapies, Lyell Immunopharma is developing revolutionizing cancer treatments that are uniquely suited to target and eliminate malignancies.
2. Autologous Cell Therapy Manufacturing:
In this segment, Lyell has established a sophisticated manufacturing facility dedicated to the large-scale production of autologous T cell therapies. This ensures a streamlined and efficient process for producing customized treatments that are derived from the patients own immune cells, thereby lowering the risk of rejection and enhancing the effectiveness of the therapies.
Products:
1. T Cell Receptor (TCR)-T Cell Therapy:
Lyell Immunopharma harnesses TCR technology to develop therapies that enhance the ability of engineered T cells to recognize and attack cancer cells. This approach stands out as it allows for targeted, antigen-specific cellular therapy. Each TCR-T cell therapy is customized according to the unique profile of a patient’s tumor, significantly improving the chances of successful treatment outcomes.
2. Chimeric Antigen Receptor (CAR)-T Cell Therapy:
The CAR-T cell therapy segment focuses on creating personalized therapies that target specific antigens expressed on cancer cells. This advanced therapeutic model has shown great promise across various cancers, particularly blood cancers. By modifying T cells to express CARs that bind to these particular tumor antigens, this therapy aims to enhance the immune systems ability to combat tumor growth effectively.
Services:
1. Research and Development:
At the heart of Lyell Immunopharmas operations lies an innovative research and development framework focused on uncovering new therapeutic targets for cancer treatment. The company is dedicated to advancing scientific knowledge in immunotherapy and continuously improving its product pipeline.
2. Clinical Trials:
The company is actively engaged in conducting clinical trials to evaluate the efficacy and safety of its cell-based therapies. By collaborating with healthcare institutions and researchers, Lyell aims to validate its innovative therapies across a range of cancer types, allowing for a robust understanding of their potential impact in clinical settings.
3. Manufacturing Services:
Lyell Immunopharma provides specialized manufacturing services for autologous T cell therapies, ensuring scalability and consistency in the production of cell-based treatments. Their facilities are equipped with cutting-edge technologies and adhere to stringent quality standards to facilitate the effective manufacturing of personalized cancer therapies.
In summary, Lyell Immunopharma Inc. is at the forefront of developing personalized cancer therapies. Through its focus on advanced cell therapy segments, innovative products like TCR-T and CAR-T cell therapies, and a commitment to high-quality services including comprehensive research, clinical trials, and manufacturing, the company is well-positioned to make a significant impact on cancer treatment and ultimately, on patient outcomes. By emphasizing customization and antigen specificity, Lyell aims to redefine the landscape of cancer therapeutics, promoting a future where more patients can benefit from effective immunotherapy solutions.
Segments:
1. Cell Therapy:
This primary segment concentrates on crafting personalized cell-based therapies tailored for individual patients. By employing advanced methods such as engineered T cell receptors (TCRs) and chimeric antigen receptor (CAR)-T cell therapies, Lyell Immunopharma is developing revolutionizing cancer treatments that are uniquely suited to target and eliminate malignancies.
2. Autologous Cell Therapy Manufacturing:
In this segment, Lyell has established a sophisticated manufacturing facility dedicated to the large-scale production of autologous T cell therapies. This ensures a streamlined and efficient process for producing customized treatments that are derived from the patients own immune cells, thereby lowering the risk of rejection and enhancing the effectiveness of the therapies.
Products:
1. T Cell Receptor (TCR)-T Cell Therapy:
Lyell Immunopharma harnesses TCR technology to develop therapies that enhance the ability of engineered T cells to recognize and attack cancer cells. This approach stands out as it allows for targeted, antigen-specific cellular therapy. Each TCR-T cell therapy is customized according to the unique profile of a patient’s tumor, significantly improving the chances of successful treatment outcomes.
2. Chimeric Antigen Receptor (CAR)-T Cell Therapy:
The CAR-T cell therapy segment focuses on creating personalized therapies that target specific antigens expressed on cancer cells. This advanced therapeutic model has shown great promise across various cancers, particularly blood cancers. By modifying T cells to express CARs that bind to these particular tumor antigens, this therapy aims to enhance the immune systems ability to combat tumor growth effectively.
Services:
1. Research and Development:
At the heart of Lyell Immunopharmas operations lies an innovative research and development framework focused on uncovering new therapeutic targets for cancer treatment. The company is dedicated to advancing scientific knowledge in immunotherapy and continuously improving its product pipeline.
2. Clinical Trials:
The company is actively engaged in conducting clinical trials to evaluate the efficacy and safety of its cell-based therapies. By collaborating with healthcare institutions and researchers, Lyell aims to validate its innovative therapies across a range of cancer types, allowing for a robust understanding of their potential impact in clinical settings.
3. Manufacturing Services:
Lyell Immunopharma provides specialized manufacturing services for autologous T cell therapies, ensuring scalability and consistency in the production of cell-based treatments. Their facilities are equipped with cutting-edge technologies and adhere to stringent quality standards to facilitate the effective manufacturing of personalized cancer therapies.
In summary, Lyell Immunopharma Inc. is at the forefront of developing personalized cancer therapies. Through its focus on advanced cell therapy segments, innovative products like TCR-T and CAR-T cell therapies, and a commitment to high-quality services including comprehensive research, clinical trials, and manufacturing, the company is well-positioned to make a significant impact on cancer treatment and ultimately, on patient outcomes. By emphasizing customization and antigen specificity, Lyell aims to redefine the landscape of cancer therapeutics, promoting a future where more patients can benefit from effective immunotherapy solutions.